Literature DB >> 15271371

MR imaging and MR spectroscopic imaging of prostate cancer.

Arumugam Rajesh1, Fergus V Coakley.   

Abstract

The primary indication for prostate MR and MR spectroscopic imaging is evaluating men with newly diagnosed prostate cancer who are deciding whether to undergo surgery or radiotherapy. Other applications of MR and MR spectroscopic imaging in prostate cancer are not defined fully. Areas of research include volumetric localization of prostate cancer, in vivo MR spectroscopic imaging at high field strength, in vitro MR spectroscopic imaging at very high field strength, novel spectroscopic markers of malignancy,and interventional MR guidance of biopsy and therapy. MR spectroscopic imaging remains a relatively novel technique, and successful implementation is demanding. Nonetheless, only MR and MR spectroscopic imaging allow structural and metabolic evaluation of prostate cancer location, aggressiveness, and stage, and MR imaging provides clinically and therapeutically relevant information on prostatic and periprostatic anatomy.

Entities:  

Mesh:

Year:  2004        PMID: 15271371     DOI: 10.1016/j.mric.2004.03.011

Source DB:  PubMed          Journal:  Magn Reson Imaging Clin N Am        ISSN: 1064-9689            Impact factor:   2.266


  8 in total

1.  Magnetic resonance imaging compatible robotic system for fully automated brachytherapy seed placement.

Authors:  Michael Muntener; Alexandru Patriciu; Doru Petrisor; Dumitru Mazilu; Herman Bagga; Louis Kavoussi; Kevin Cleary; Dan Stoianovici
Journal:  Urology       Date:  2006-12       Impact factor: 2.649

Review 2.  Role of magnetic resonance imaging and magnetic resonance spectroscopic imaging before and after radiotherapy for prostate cancer.

Authors:  Antonio C Westphalen; David A McKenna; John Kurhanewicz; Fergus V Coakley
Journal:  J Endourol       Date:  2008-04       Impact factor: 2.942

3.  Prostate cancer: prediction of biochemical failure after external-beam radiation therapy--Kattan nomogram and endorectal MR imaging estimation of tumor volume.

Authors:  Antonio C Westphalen; Walter J Koff; Fergus V Coakley; Valdair F Muglia; John M Neuhaus; Ralph T Marcus; John Kurhanewicz; Rebecca Smith-Bindman
Journal:  Radiology       Date:  2011-08-24       Impact factor: 11.105

4.  Role of magnetic resonance spectroscopic imaging ([¹H]MRSI) and dynamic contrast-enhanced MRI (DCE-MRI) in identifying prostate cancer foci in patients with negative biopsy and high levels of prostate-specific antigen (PSA).

Authors:  V Panebianco; A Sciarra; M Ciccariello; D Lisi; S Bernardo; S Cattarino; V Gentile; R Passariello
Journal:  Radiol Med       Date:  2010-09-17       Impact factor: 3.469

5.  Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection.

Authors:  Antonio C Westphalen; Fergus V Coakley; Mack Roach; Charles E McCulloch; John Kurhanewicz
Journal:  Radiology       Date:  2010-06-15       Impact factor: 11.105

6.  Endorectal MRI after radiation therapy: questioning the sextant analysis.

Authors:  Shilpa R Kumbhani; Fergus V Coakley; Charles E McCulloch; Z Jane Wang; John Kurhanewicz; Mack Roach; Antonio C Westphalen
Journal:  J Magn Reson Imaging       Date:  2011-05       Impact factor: 4.813

7.  Performance comparison of 1.5-T endorectal coil MRI with 3.0-T nonendorectal coil MRI in patients with prostate cancer.

Authors:  Zarine K Shah; Saba N Elias; Ronney Abaza; Debra L Zynger; Lawrence A DeRenne; Michael V Knopp; Beibei Guo; Ryan Schurr; Steven B Heymsfield; Guang Jia
Journal:  Acad Radiol       Date:  2015-01-08       Impact factor: 3.173

8.  Incorporating Oxygen-Enhanced MRI into Multi-Parametric Assessment of Human Prostate Cancer.

Authors:  Heling Zhou; Rami R Hallac; Qing Yuan; Yao Ding; Zhongwei Zhang; Xian-Jin Xie; Franto Francis; Claus G Roehrborn; R Douglas Sims; Daniel N Costa; Ganesh V Raj; Ralph P Mason
Journal:  Diagnostics (Basel)       Date:  2017-08-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.